SHORT REPORTS |
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, and Department of Psychiatry, HUCH, Peijas Hospital, Health Care District of Helsinki and Uusimaa, Vantaa
Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, and Department of Psychiatry, Helsinki University Central Hospital, Helsinki, Finland
Correspondence: Erkki T. Isometsä, MD, PhD, Institute of Clinical Medicine, Department of Psychiatry, P.O. Box 22 (Välskärinkatu 12 A), 00014 University of Helsinki, Finland. Email: erkki.isometsa{at}hus.fi
None. Funding detailed in Acknowledgements.
Practice guidelines endorse maintenance antidepressant treatment for recurrent major depressive disorder. In the Vantaa Depression Study, we followed 218 psychiatric patients with major depressive disorder for up to 5 years with a life-chart. Of these patients, 86 (39.4%) had more than three lifetime episodes and an indication for maintenance pharmacotherapy. However, of these, only 57% received treatment and only for 16% of the time indicated. Good adherence to pharmacotherapy in the acute phase independently predicted maintenance treatment. The tertiary preventive impact of maintenance treatment may remain limited, as many patients with major depressive disorder either do not receive it, or receive it for too short a period.